Search

Displaying results 5551 - 5560 of 10000 in total
  1. Drug

    AL-034

    go.drugbank.com/drugs/DB17471
    Investigational

    AL-034 (TQ-A3334) is an oral toll-like receptor 7 agonist developed for the treatment of chronic hepatitis B (CHB) viral infection.

  2. Drug

    CTB001

    go.drugbank.com/drugs/DB18316
    Investigational

    CTB001 is an anti-claudin 18.2 autologous chimeric antigen receptor (CAR) T-cell therapy under investigation for the treatment of gastric cancers.[L48146]

  3. Drug

    Roledumab

    go.drugbank.com/drugs/DB16317
    Investigational

    Roledumab is under investigation in clinical trial NCT02287896 (Pharmacokinetics and Safety of Roledumab in Rhd-negative Pregnant Women Carrying an Rhd-positive Foetus).

  4. Drug

    Tirabrutinib

    go.drugbank.com/drugs/DB15227
    Investigational

    Tirabrutinib is under investigation in clinical trial NCT02626026 (Safety and Pharmacokinetics of GS-4059 in Healthy Volunteers and Subjects With Rheumatoid Arthritis (RA)).

  5. Drug

    2-Hydroxyestradiol

    go.drugbank.com/drugs/DB07706
    Experimental

    2-Hydroxyestradiol is classified as an endogenous steroid, catechol estrogen, and metabolite of estradiol. It is also a positional isomer of estriol. [A31630]

  6. Drug

    WIN 55212-2

    go.drugbank.com/drugs/DB13950
    Experimental

    WIN 55,212-2 is a chemical described as an aminoalkylindole derivative, which produces effects similar to those of cannabinoids such as tetrahydrocannabinol (THC) but has an entirely different chemical … It is a potent cannabinoid receptor agonist that has been found to be a potent analgesic in a rat model of neuropathic pain. It activates p42 and p44 MAP kinase via receptor-mediated signaling.

  7. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    This follows an earlier decision to discontinue development of eplivanserin for schizophrenia. … In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant.

  8. Drug

    EMZ702

    go.drugbank.com/drugs/DB05021
    Investigational

    EMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments. … EMZ702 has an excellent safety profile and the combination of EMZ702 with interferon and ribavirin in surrogate models for hepatitis C has demonstrated a two to three fold increase in anti-viral potency

  9. Drug

    Geneticin

    go.drugbank.com/drugs/DB04263
    Experimental

    Resistance to Geneticin is conferred by the neo gene from Tn5 encoding an aminoglycoside 3‘-phosphotransferase, APH 3‘ II. … Geneticin (also known as G418) is an aminoglycoside antibiotic similar in structure to gentamicin B1, produced by Micromonospora rhodorangea.

  10. Drug

    Sodium zirconium cyclosilicate

    go.drugbank.com/drugs/DB14048
    ApprovedInvestigational

    acts as a highly selective potassium removing agent. … Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that

    Categories: Compounds used in a research, industrial, or household setting